DPCO may impact domestic revenue of pharma cos in 2014: D&B

Image
Press Trust of India Mumbai
Last Updated : Dec 29 2013 | 11:35 AM IST
Implementation of the new pricing policy is likely to translate into weak domestic revenue generation for pharma companies in 2014, says a research report.
"Implementation of the Drug Policy Control Order (DPCO) 2013 by the New Pharmaceutical Pricing Authority (NPPA) with effect from May 15, 2013, which put a cap on the prices of 348 essential drugs, is likely to impact domestic revenue generation of both homegrown and multinational drug companies in 2014," Dun & Bradstreet said in its report.
The impact of the new drug pricing policy and regulatory intervention has already started influencing the growth performance of the overall pharma industry.
Slowing quarterly net sales growth to 9 and 12 per cent during Q2 & Q3 of 2013 (period during which DPCO was implemented) respectively against over 15 per cent growth during the same period previous year well reflects the impact of DPCO as well as the slowdown in demand, the report said.
Compliance to this regulation may continue to create the pressure on pharma companies' profitability in 2014, it said.
The pharma industry has exhibited a stellar performance in the past and has grown unabated at an estimated CAGR of 13 per cent during FY2009-13, driven by domestic and export-led demand.
Lower cost of production and availability of highly skilled labour pool at low cost has helped domestic pharma firms to innovate and develop generic substitutes of patented drugs at a fraction of cost incurred in developed markets.
Though the pharma industry has remained shock-proof to recession in the past, currently companies in this sector are also facing the heat of slowing economic growth.
The cumulative sale for first nine months of 2013 grew by just 9 per cent against 17.4 per cent in the previous year.
Moreover, the industry is facing stringent regulatory and quality norms both at global and domestic front.
Rising government intervention is expected to impact industry's performance in the near-term, but such interventions are necessary to bring the country at par with global standards, D&B said.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 29 2013 | 11:35 AM IST

Next Story